Below are some of the on-going research projects within the charity;
As more people survive into old age, the prevalence of heart failure (HF), one of the most common and debilitating diseases in older people, will rise still further. Delaying or preventing HF will have great benefit to those at personal risk, their families, society and the economy. HOMAGE aims to provide a biomarker (BM) approach that will  help identify patients at high risk of developing HF before the onset of symptoms and . subsets of patients who are more likely to respond to specifically targeted therapies (personalised medicine).
Development of scalable new model(s) focussed on care coordination and care provision for medically complex, co-morbid chronic disease patient segments focusing on HF.
This research is study between hospital-based clinical teams in both Ireland and the UK sponsored by Enterprise Ireland, in conjunction with its partners UCD and their commercial partners ResMed, Boston Scientific and Cardiomark. The aims of the project can be summarised as; Identify and describe the components of the patient pathway from pre-hospitalisation through to discharge. Develop an infrastructure for efficient collection of patient pathway information by medical and nursing personnel. Perform a complete literature review of existing and emerging HF management strategies (encompassing processes, technologies, etc.). Develop a novel solution for heart failure management, which overcomes barrier(s) seen in current patient pathways and is applicable internationally.
The Metabolic Road to Diastolic Heart Failure (MEDIA): Metabolic risk – diastolic Heart Failure (METR-DHF) Sub-study
In 2012, the STOP HF Screening Programme began sharing our information with other specialist research centres throughout Europe in an effort to improve detection and prevention of Diastolic Heart Failure (DHF) in the at risk population. It is believed that a collaborative approach to research in this area will be the fastest and most effective way to improve care.
Sleep apnoea in patients with dipping and non-dipping patterns of hypertension.
We are working with our Respiratory colleagues looking at the prevalence of sleep apnoea in patients with dipping and non-dipping patterns of hypertension.
Impact of Eplerenone on Asymptomatic Left Ventricular Diastolic Dysfunction in Diabetic Patients
The aim of this drug trial is to see whether Eplerenone can help prevent the progression of diastolic dysfunction (stiffness of the heart muscle) in people with diabetes who show evidence of diastolic dysfunction but do not have HF. Improvement in cardiac structure and function, as well as change in biomarker profiles are study end points.
The ‘Natural history of Diabetic Cardiomyopathy’ Project
The public health challenge posed by heart failure will escalate with the emerging epidemic of diabetes mellitus. One of the major health care consequences of diabetes is cardiovascular disease, with a specific predisposition to ventricular dysfunction. This diabetic cardiomyopathy is most frequently represented by left ventricular diastolic dysfunction (LVDD). LVDD is linked to preserved ejection fraction heart failure. At present we lack a clear epidemiological study of LVDD in diabetic patients and as a result it is not clear who will develop LVDD and who will demonstrate progressive dysfunction, a group at heightened risk of heart failure. This project plans to investigate the natural history of LVDD in a diabetic population, providing a basis for understanding the disease and its progression, and to develop an effective preventative strategy by improving our diagnostic and disease monitoring capacity with the application of novel biomarker strategies.
COMmunity Project for cardiovAscular Risk Evaluation (COMPARE)
Cardiovascular risk factors are common, predominantly found in the community and sometimes difficult to manage. This large community based study compares the impact of a low-intensity community screening programme on cardiovascular risk factors and health behaviours in patients with risk factors.